Company profile
ADICET BIO, INC.
NASDAQ:ACETBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PRULACABTAGENE LEUCEL | phase1 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04735471 | phase1 | terminated | 2021-03-04 | 2025-02-03 | Adicet Therapeutics | A Phase 1 Study of ADI-001 in B Cell Malignancies |
| NCT07100873 | phase1 | recruiting | 2025-10-10 | 2027-03-30 | Adicet Therapeutics | A Phase 1 Study of ADI-001 in Rheumatoid Arthritis |
| NCT06375993 | phase1 | enrolling_by_invitation | 2024-11-10 | 2026-12-01 | Adicet Therapeutics | A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease |
| NCT07793435 | phase1_2 | not_yet_recruiting | 2026-09-01 | 2028-10-01 | Adicet Therapeutics | A Phase 1/2 Trial of ADI-212 in mCRPC |
| NCT06480565 | phase1_2 | active_not_recruiting | 2024-12-12 | 2026-12-01 | Adicet Therapeutics | A Phase 1/2 Trial of ADI-270 in ccRCC |
FDA applications (0)
No records yet.